Rebirthel Co., Ltd
- Biotech or pharma, therapeutic R&D
Rebirthel Co., Ltd is a pre-clinical stage Japanese biotech company.
We are developing "allogeneic off-the-shelf-typed regenerated immune cell therapy, especially cytotoxic T cell therapy”.
We were established by Professor Hiroshi Kawamoto in Kyoto University in 2019.
Rebirthel has fundamental and essential patented technologies to realize allogeneic cell therapies regenerated from pluripotent stem cells.
We have two business models.
One is an in-house development business, and these are preparing clinical trial for AML, solid tumor, and infectious disease.
Another is license business, and these are licensing our patented technologies to pharmaceutical/biotech companies for developing clinical application. We have already engaged with some pharma/biotech companies.
In this convention, we are looking for more partnering/licensing opportunities or fundraising opportunities.
NO MEETING REQUESTS FROM DIAGNOSTICS, CROs, CMOs, HEALTH IT, OR SERVICE PROVIDERS PLEASE
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}